Study of GS-0415 and How It Works in People With HIV
Public ClinicalTrials.gov record NCT07719491. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A First-in-Human Phase 1b, Single-Blind, Placebo-controlled Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate Safety and Pharmacokinetics of GS-0415 in People With HIV-1 Who Are Virologically Suppressed on Antiretroviral Treatment
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goals of this clinical study are to learn more about the study drug GS-0415, safety, tolerability, and pharmacokinetics (PK) of single ascending doses (SAD) and multiple ascending doses (MAD) of subcutaneous (SC) and intravenous (IV) GS-0415 in people with HIV-1 (PWH) on antiretroviral treatment. The primary objectives of this study are to evaluate the safety and tolerability of escalating, single and multiple subcutaneous (SC) and intravenous (IV) doses of GS-0415, administered in PWH who are virologically suppressed on antiretroviral therapy (ART) and to evaluate the pharmacokinetics (PK) of GS-0415.
Study identification
- NCT ID
- NCT07719491
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 112 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 21, 2026
- Primary completion
- Jul 31, 2029
- Completion
- Jul 31, 2029
- Last update posted
- Aug 31, 2026
2026 – 2029
United States locations
- U.S. sites
- 7
- U.S. states
- 7
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Kaiser Permanente Los Angeles Medical Center | Los Angeles | California | 90027 | Recruiting |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 20007 | Recruiting |
| Triple O Research Institute, P.A. | West Palm Beach | Florida | 33407 | Recruiting |
| PPD Development, LP | Las Vegas | Nevada | 89113 | Recruiting |
| St. Michaels Medical Center | Newark | New Jersey | 07102 | Not yet recruiting |
| Jacobi Medical Center | The Bronx | New York | 10461 | Recruiting |
| The Ohio State University Medical Center Infectious Diseases Clinic | Columbus | Ohio | 43210 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated HIV -1 Infection trials
Other public records listing HIV -1 Infection. Sorted by last update posted; newest first. Not a recommendation.
- NCT07698600: A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIV Recruiting
- NCT07708727: Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment Recruiting
- NCT07683000: Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens Recruiting
- NCT03729778: Impact of HIV-1 and Aging on Mucosal Vaccine Responses Active, not recruiting
- NCT05459077: Addressing Barriers to Anti-hypertensive Medication Adherence Among PLWH Who Have Achieved Viral Suppression Not yet recruiting
- NCT07645287: A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1 Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07719491, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 31, 2026 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07719491 live on ClinicalTrials.gov.